Inter-observer agreement in reporting HER 2 Neu protein over expression by immunohistochemistry

Indian Journal of Pathology and Microbiology

Volumn 57, Issue 2, 2014, Pages 201-204

  Al Haddabi, Ibrahim ^a   Qureshi, Asim ^a   Saparamadu, Anna ^a   Al Hamdani, Aisha ^a   Al Riyami, Marwa ^a   Ganguly, Shyam ^a  

^a SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

HER 2 Neu; immunohistochemistry; peer review

Indexed keywords

EOSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEMATOXYLIN;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CLINICAL ARTICLE; CRONBACH ALPHA COEFFICIENT; DESCRIPTIVE RESEARCH; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INTER OBSERVER VARIABILITY; INTERNAL CONSISTENCY; KAPPA STATISTICS; MEDICAL RECORD REVIEW; PATHOLOGIST; PEER REVIEW; PROTEIN EXPRESSION; REPRODUCIBILITY; STATISTICAL ANALYSIS; TERTIARY CARE CENTER; BREAST NEOPLASMS; GENE EXPRESSION; HEALTH SERVICES RESEARCH; OBSERVER VARIATION; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; STANDARDS;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; HEALTH SERVICES RESEARCH; HUMANS; IMMUNOHISTOCHEMISTRY; OBSERVER VARIATION; PATHOLOGY; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; TERTIARY CARE CENTERS;

EID: 84903278283     PISSN: 03774929     EISSN: 09745130     Source Type: Journal    
DOI: 10.4103/0377-4929.134663     Document Type: Article

References (15)

1. Tímár J. Role of contemporary pathological diagnostics in the personalized treatment of cancer. Magy Onkol 2013;57:26-32.
2. Manton DJ, Chaturvedi A, Hubbard A, Lind MJ, Lowry M, Maraveyas A, et al. Neoadjuvant chemotherapy in breast cancer: Early response prediction with quantitative MR imaging and spectroscopy. Br J Cancer 2006;94:427-35. (Pubitemid 43237566)
3. Perez EA, Press MF, Dueck AC, Jenkins RB, Kim C, Chen B, et al. Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005). Breast Cancer Res Treat 2013;138:99-108.
4. Chia YH, Ellis MJ, Ma CX. Neoadjuvant endocrine therapy in primary breast cancer: Indications and use as a research tool. Br J Cancer 2010;103:759-64.
5. Perez EA, Romond EH, Suman VJ, Jeong JH, Davidson NE, Geyer CE Jr, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: Joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol 2011;29:3366-73.
6. Criscitiello C, Metzger-Filho O, Saini KS, de Castro G Jr, Diaz M, La Gerche A, et al. Targeted therapies in breast cancer: Are heart and vessels also being targeted? Breast Cancer Res 2012;14:209.
7. Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M. C-erbB-2 immunostaining: Problems with interpretation. J Clin Pathol 1994;47:816-22.
8. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43. (Pubitemid 46174133)
9. Cell Markers And Cytogenetics Committees College Of American Pathologists. Clinical laboratory assays for HER-2/neu amplification and overexpression: Quality assurance, standardization, and proficiency testing. Arch Pathol Lab Med 2002;126:803-8.
10. Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H. Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol 2002;118:693-8. (Pubitemid 37046313)
11. Lacroix-Triki M, Mathoulin-Pelissier S, Ghnassia JP, Macgrogan G, Vincent-Salomon A, Brouste V, et al. High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: A multicentre GEFPICS study. Eur J Cancer 2006;42:2946-53. (Pubitemid 44667473)
12. Turashvili G, Leung S, Turbin D, Montgomery K, Gilks B, West R, et al. Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): Pathologist assessment compared to quantitative image analysis. BMC Cancer 2009;9:165.
13. Tsuda H, Sasano H, Akiyama F, Kurosumi M, Hasegawa T, Osamura RY, et al. Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int 2002;52:126-34. (Pubitemid 34298099)
14. Cross S. Observer accuracy in estimating proportions in images: Implications for the semi quantitative assessment of staining reactions and a proposal for a new system. J Clin Pathol 2001;54:385-90. (Pubitemid 32458138)
15. Schnitt SJ, Jacobs TW. Current status of HER2 testing: Caught between a rock and a hard place. Am J Clin Pathol 2001;116:806-10. (Pubitemid 33108149).